Antibiotic use and childhood body mass index trajectory

B S Schwartz1,2,3,4, J Pollak1, L Bailey-Davis4

  • 1Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Insights

Antibiotic use in children is linked to weight gain, with effects persisting and progressing over time. This study reveals age-dependent impacts on body mass index (BMI) trajectories throughout childhood.

Area of Science:

  • Pediatric Health
  • Pharmacology
  • Epidemiology

Background:

  • Antibiotics are frequently prescribed for children.
  • Early antibiotic exposure is associated with weight gain.
  • Limited large-scale, population-based, longitudinal data exist for healthy children across a full age range.

Purpose of the Study:

  • To investigate the association between antibiotic orders and body mass index (BMI) trajectories in children aged 3-18 years.
  • To examine reversible, persistent, and progressive effects of antibiotic use on BMI.
  • To determine if these associations vary by age.

Main Methods:

  • Utilized electronic health record data from 163,820 children (aged 3-18 years).
  • Employed mixed-effects linear regression to model BMI growth curve trajectories.
  • Assessed three types of antibiotic associations: reversible, persistent, and progressive, analyzing age-specific effects.

Main Results:

  • A reversible association between antibiotic orders and short-term BMI gain was observed, with effects peaking in mid-adolescence.
  • A persistent association was found, strengthening with increasing age.
  • Progressive weight gain was linked to cumulative antibiotic orders, independent of age.
  • Macrolide use was associated with the largest weight gain at age 15.

Conclusions:

  • Antibiotic use demonstrates reversible, persistent, and progressive effects on BMI trajectories in children.
  • These effects are age-dependent and influence weight gain throughout childhood, not solely in early years.
  • Findings highlight the long-term impact of antibiotic exposure on pediatric weight trajectories.
Abstract

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
34
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
732
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
374
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
464
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
769
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
332